Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$13.56 - $20.78 $4.13 Million - $6.32 Million
304,240 Added 92.34%
633,718 $9.15 Million
Q4 2023

Feb 14, 2024

SELL
$14.18 - $22.31 $380,123 - $598,064
-26,807 Reduced 7.52%
329,478 $7.09 Million
Q3 2023

Nov 14, 2023

BUY
$18.22 - $25.85 $3.35 Million - $4.75 Million
183,807 Added 106.57%
356,285 $6.85 Million
Q2 2023

Aug 14, 2023

SELL
$22.62 - $39.32 $4.44 Million - $7.71 Million
-196,128 Reduced 53.21%
172,478 $4.38 Million
Q1 2023

May 15, 2023

BUY
$30.17 - $41.11 $1.52 Million - $2.07 Million
50,242 Added 15.78%
368,606 $13.3 Million
Q4 2022

Feb 14, 2023

SELL
$36.43 - $49.4 $744,119 - $1.01 Million
-20,426 Reduced 6.03%
318,364 $12.6 Million
Q3 2022

Nov 14, 2022

SELL
$40.66 - $53.03 $6.3 Million - $8.22 Million
-154,951 Reduced 31.38%
338,790 $15.8 Million
Q2 2022

Aug 15, 2022

BUY
$40.85 - $77.67 $8.86 Million - $16.8 Million
216,860 Added 78.32%
493,741 $21.6 Million
Q1 2022

May 16, 2022

BUY
$59.95 - $92.06 $10.7 Million - $16.4 Million
177,876 Added 179.66%
276,881 $20 Million
Q4 2021

Feb 14, 2022

SELL
$81.07 - $121.29 $5.26 Million - $7.86 Million
-64,837 Reduced 39.57%
99,005 $8.03 Million
Q3 2021

Nov 15, 2021

BUY
$101.99 - $166.36 $16.3 Million - $26.6 Million
160,143 Added 4329.36%
163,842 $19.1 Million
Q2 2021

Aug 16, 2021

BUY
$141.6 - $179.06 $523,778 - $662,342
3,699 New
3,699 $613,000
Q1 2020

May 15, 2020

SELL
$70.23 - $144.31 $4.86 Million - $9.99 Million
-69,233 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$76.41 - $117.54 $5.29 Million - $8.14 Million
69,233 New
69,233 $8.14 Million

Others Institutions Holding NVRO

About NEVRO CORP


  • Ticker NVRO
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 35,387,800
  • Market Cap $116M
  • Description
  • Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It...
More about NVRO
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.